DK1515702T6 - Misbrugssikret indgivelsesform - Google Patents

Misbrugssikret indgivelsesform Download PDF

Info

Publication number
DK1515702T6
DK1515702T6 DK03735628.4T DK03735628T DK1515702T6 DK 1515702 T6 DK1515702 T6 DK 1515702T6 DK 03735628 T DK03735628 T DK 03735628T DK 1515702 T6 DK1515702 T6 DK 1515702T6
Authority
DK
Denmark
Prior art keywords
protected
abuse
submission form
aqueous liquid
administration form
Prior art date
Application number
DK03735628.4T
Other languages
English (en)
Other versions
DK1515702T3 (da
Inventor
Johannes Bartholomäus
Heinrich Kugelmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29737609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1515702(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of DK1515702T3 publication Critical patent/DK1515702T3/da
Application granted granted Critical
Publication of DK1515702T6 publication Critical patent/DK1515702T6/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03735628.4T 2002-06-17 2003-06-16 Misbrugssikret indgivelsesform DK1515702T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10227077 2002-06-17
DE10250083A DE10250083A1 (de) 2002-06-17 2002-10-25 Gegen Missbrauch gesicherte Darreichungsform
PCT/EP2003/006314 WO2003105808A1 (de) 2002-06-17 2003-06-16 Gegen missbrauch gesicherte darreichungsform

Publications (2)

Publication Number Publication Date
DK1515702T3 DK1515702T3 (da) 2009-01-12
DK1515702T6 true DK1515702T6 (da) 2022-04-11

Family

ID=29737609

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03735628.4T DK1515702T6 (da) 2002-06-17 2003-06-16 Misbrugssikret indgivelsesform

Country Status (11)

Country Link
EP (1) EP1515702B3 (da)
JP (2) JP2005534664A (da)
AT (1) ATE411007T1 (da)
AU (1) AU2003237944A1 (da)
CY (1) CY1108682T1 (da)
DE (2) DE10250083A1 (da)
DK (1) DK1515702T6 (da)
ES (1) ES2315505T7 (da)
PT (1) PT1515702E (da)
SI (1) SI1515702T1 (da)
WO (1) WO2003105808A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE50309605D1 (de) * 2002-11-22 2008-05-21 Gruenenthal Gmbh Verwendung von (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexan-1,3-diol zur Behandlung von Entzündungsschmerz
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
AR053304A1 (es) * 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
FI1765303T4 (fi) * 2004-07-01 2023-01-31 Väärinkäytöltä suojattu oraalinen tabletti
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
CA2766172C (en) 2009-07-22 2017-09-12 Lutz Barnscheid Oxidation-stabilized tamper-resistant dosage form
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
DE20220917U1 (de) * 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
MXPA04001208A (es) * 2001-08-06 2004-07-08 Euro Celtique Sa Composiciones y metodos para evitar el abuso de los opioides.
KR20190026065A (ko) 2010-07-23 2019-03-12 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정

Also Published As

Publication number Publication date
DK1515702T3 (da) 2009-01-12
DE10250083A1 (de) 2003-12-24
ATE411007T1 (de) 2008-10-15
DE50310649D1 (de) 2008-11-27
EP1515702B3 (de) 2022-01-12
EP1515702B1 (de) 2008-10-15
JP2005534664A (ja) 2005-11-17
SI1515702T1 (sl) 2009-04-30
ES2315505T3 (es) 2009-04-01
CY1108682T1 (el) 2014-04-09
AU2003237944A1 (en) 2003-12-31
EP1515702A1 (de) 2005-03-23
ES2315505T7 (es) 2022-04-07
PT1515702E (pt) 2008-12-29
WO2003105808A1 (de) 2003-12-24
JP2011251982A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
DK1515702T6 (da) Misbrugssikret indgivelsesform
SG147485A1 (en) Pharmaceutical compositions for prevention of overdose or abuse
EA200200858A1 (ru) Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы
BRPI0410555A (pt) preparação sólida
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
HRP20020158B1 (en) Action of synergistic combination
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
WO2005017097A3 (en) Quorum sensing and biofilm formation
ATE506959T1 (de) Verwendung von il-18 inhibitoren
DK1327143T3 (da) Krystalstruktur af BACE og anvendelse deraf
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
BR0013012A (pt) Composição contendo substância ativa, sua produção e seu uso
EP1354602A4 (en) MEDICAL COMPOSITIONS WITH DIURETIC AGENT AND IMPROVING INSULIN RESISTANCE
NO20020829D0 (no) Ny anvendelse av docetaxel for behandling av hepatoma
ATE297738T1 (de) Verfahren zur erhöhung der wachsamkeit durch verabreichung von vomeropherin und vomeropherin emittierende alarmvorricthung
RS51081B (sr) Nova sinergistička kombinacija koja uključuje roflumilast i formoterol
MA28292A1 (fr) Forme posologique solide
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
YU102403A (sh) Postupci za dizajniranje leka, baziranog na strukturi, za identifikovanje inhibitora d-ala-d-ala ligaze, kao antibakterijskih lekova
UY26618A1 (es) Composiciones farmacéuticas de inhibidores de la gcomposiciones farmacéuticas de inhibidores de la glucógeno-fosforilasa
DOP2002000421A (es) Composiciones farmaceuticas que contienen conjunto de pollimero y farmaco.
MA27098A1 (fr) Composition pharmaceutique orodispersible de piribedil